OM
OUP Management Co., LLC
13F filer · CIK 0001880124Last filed Nov 9, 2023
Inactive · not filing 13F
13F portfolio value$44.5MU.S. long equity reported on 13F
Positions90 new · 1 closed
Net flow last quarter-$12.5MBuys minus sells
Top 10 positions weight83.9%Concentration
Holdings
13F · last 4 quarters freeScroll for earlier quarters
| Company | Value | % of portfolio | % of company | POSITION CHANGE qoq % | First reported |
|---|---|---|---|---|---|
| Q3 2023Reported Nov 9, 20239 positions | |||||
| CPCNTACentessa Pharmaceuticals PLC | $19M | 42.74% | 3.01% | Not reported | Q4 2021 |
| $8.19M | 18.43% | Not reported | Not reported | Q4 2021 | |
| $6.07M | 13.66% | 1.93% | Not reported | Q4 2021 | |
| GGRPHGraphite Corp. | $1.01M | 2.27% | 0.20% | Not reported | Q4 2021 |
| $914K | 2.06% | 0.56% | Not reported | Q4 2021 | |
| $794K | 1.79% | 0.55% | Not reported | Q4 2021 | |
| ETEFTReFFECTOR Therapeutics, Inc. | $615K | 1.38% | 1.64% | Not reported | Q4 2021 |
| $384K | 0.86% | 0.97% | Not reported | Q4 2021 | |
| $301K | 0.68% | 0.47% | Not reported | Q4 2021 | |
| Q2 2023Reported Aug 7, 202310 positions | |||||
| CPCNTACentessa Pharmaceuticals PLC | $18.2M | 31.01% | 3.08% | Not reported | Q4 2021 |
| $12.5M | 21.26% | 0.56% | Not reported | Q4 2021 | |
| $10.4M | 17.66% | Not reported | Not reported | Q4 2021 | |
| $6.19M | 10.56% | 2.14% | Not reported | Q4 2021 | |
| $1.16M | 1.97% | 0.56% | Not reported | Q4 2021 | |
| GGRPHGraphite Corp. | $1.06M | 1.80% | 0.20% | Not reported | Q4 2021 |
| $966K | 1.65% | 0.56% | Not reported | Q4 2021 | |
| ETEFTReFFECTOR Therapeutics, Inc. | $852K | 1.45% | 1.67% | Not reported | Q4 2021 |
| $591K | 1.01% | 0.98% | Not reported | Q4 2021 | |
| $361K | 0.62% | 0.47% | Not reported | Q4 2021 | |
| Q1 2023Reported Apr 24, 202312 positions | |||||
| $12.2M | 24.30% | Not reported | Not reported | Q4 2021 | |
| CPCNTACentessa Pharmaceuticals PLC | $11.3M | 22.57% | 3.09% | Not reported | Q4 2021 |
| $7.69M | 15.34% | 0.56% | Not reported | Q4 2021 | |
| $4.72M | 9.42% | 2.16% | Not reported | Q4 2021 | |
| $2.4M | 4.78% | 0.19% | -66.9% | Q4 2021 | |
| $2.02M | 4.02% | 0.56% | Not reported | Q4 2021 | |
| $1.49M | 2.98% | 0.12% | Not reported | Q4 2022 | |
| $1.2M | 2.39% | 0.56% | Not reported | Q4 2021 | |
| GGRPHGraphite Corp. | $995K | 1.99% | 0.20% | Not reported | Q4 2021 |
| $847K | 1.69% | 1.00% | Not reported | Q4 2021 | |
| ETEFTReFFECTOR Therapeutics, Inc. | $362K | 0.72% | 2.44% | Not reported | Q4 2021 |
| $361K | 0.72% | 0.47% | Not reported | Q4 2021 | |
| Q4 2022Reported Feb 2, 202312 positions | |||||
| $17.7M | 28.88% | Not reported | Not reported | Q4 2021 | |
| CPCNTACentessa Pharmaceuticals PLC | $9.11M | 14.87% | 3.10% | Not reported | Q4 2021 |
| $8.61M | 14.05% | 2.16% | Not reported | Q4 2021 | |
| $8.37M | 13.67% | 0.56% | -50.0% | Q4 2021 | |
| $4.06M | 6.63% | 0.59% | Not reported | Q4 2021 | |
| $2.49M | 4.07% | 0.57% | Not reported | Q4 2021 | |
| $2.25M | 3.68% | 0.12% | New | Q4 2022 | |
| GGRPHGraphite Corp. | $1.35M | 2.20% | 0.20% | Not reported | Q4 2021 |
| $1.34M | 2.18% | 30.39% | Not reported | Q4 2021 | |
| $975K | 1.59% | 0.56% | Not reported | Q4 2021 | |
| ETEFTReFFECTOR Therapeutics, Inc. | $439K | 0.72% | 61.51% | Not reported | Q4 2021 |
| $431K | 0.70% | 0.47% | Not reported | Q4 2021 | |
Premium opens every quarter this fund has filed